Recommendation of the President – on the legitimacy of qualifying the health care service “Care for families at high hereditary risk for retinoblastoma or von Hippel-Lindau disease (VHL)” – as a guaranteed outpatient specialised care service
On 21 June 2022 the President of the Agency for Health Technology Assessment and Tariff System issued the following recommendation:
Recommendation No. 62/2022 of 21 June 2022 of the President of the Agency for Health Technology Assessment and Tariff System on the legitimacy of qualifying the health care service “Care for families at high hereditary risk for retinoblastoma or von Hippel-Lindau disease (VHL)” – as a guaranteed outpatient specialised care service.